Flibanserin CAS 167933-07-5 Pharmaceutical Raw Materials For Female Sex Enhance

Place of Origin CHINA
Brand Name XRD
Certification GMP
Model Number 167933-07-5
Minimum Order Quantity negotiable
Price Inquiry for Negotiable
Packaging Details 1-2 Kg / Aluminum Foil Bag, 25kg/ Drum, as Require
Delivery Time 1-2days after payment received
Payment Terms T/T, Western Union,Bitcoin
Supply Ability 100kg/year

Contact me for free samples and coupons.

Whatsapp:0086 18588475571

Wechat: 0086 18588475571

Skype: sales10@aixton.com

If you have any concern, we provide 24-hour online help.

Product Details
Cas No. 167933-07-5 Product NameEszopiclone Flibanserin
Usage Pharmaceutical Raw Material Appearance White Powder
Assay 99% Flibanserin Grade Pharmaceutical Grade
Storage Cool Dried Storage Application Pharmaceutical Raw Intermediates
High Light

pharm raw material


research chemicals

Leave a Message
Product Description

Flibanserin CAS 167933-07-5 Pharmaceutical Raw Materials For Female Sex Enhance




Product name: Flibanserin powder
Another name: Bimt 17
Chemical formula: C20H21F3N4O
Molecular weight: 426.86
CAS number: 167933-07-5
Appearance: White Crystal Powder
Purity (HPLC): 99.0%


Flibanserin, is a medication approved for the treatment of pre-menopausal women withhypoactive desire disorder (HSDD). The medication increases the number of satisfying events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low. The side effects of dizziness, sleepiness, and nausea occur about three to four times more often.


Flibanserin is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman's craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues.

Flibanserin HCL (INN, USAN) (developmental code name BIMT-17; proposed trade names Girosa and Addyi) is a drug that is being studied as a non-hormonal treatment for pre-menopausal women with hypoactive desire disorder (HSDD). Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. Food and Drug Administration. The rights to the drug were then transferred to Sprout Pharmaceuticals, which is continuing the drug development process. On June 4, 2015, the panel to the FDA recommended approval of the drug by 18–6.




Flibanserin, a drug used to increase female libido, reduces the suppression of ly active serotonin to increase dopamine levels that stimulate libido. Low libido (HSDD) in premenopausal women shows good efficacy and tolerability.

Flibanserin is used for hypoactive desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying events”.In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of “satisfying events” from 2.7 to 3.7 times a month.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.

The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying events (SSEs) and the other for desire. Each of the 3 trials also had a secondary endpoint that measured distress related to desire. All three trials showed that flibanserin produced an increase in the number of SSEs and reduced distress related to desire. The first two trials used an electronic diary to measure desire, and did not find an increase. These two trials also measured desire using the Female Function index (FSFI) as a secondary endpoint, and an increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for desire in the third trial, and again showed a statistically significant increase.

Flibanserin CAS 167933-07-5 Pharmaceutical Raw Materials For Female Sex Enhance 0

Flibanserin CAS 167933-07-5 Pharmaceutical Raw Materials For Female Sex Enhance